3-[(2,2-difluorocyclopropyl)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2(3H)-one | 1345961-19-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 3-[(2,2-difluorocyclopropyl)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2(3H)-one
• 英文别名: 3-[(2,2-difluorocyclopropyl)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-one
• CAS: 1345961-19-4
• 化学式: C₁₇H₂₀BF₂NO₃S
• 分子量: 367.225
• InChiKey: VAQJNYKQLXPAMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.02
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  64.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-[(2,2-difluorocyclopropyl)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2(3H)-one 在 双氧水 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.5h， 生成 3-[(2,2-difluorocyclopropyl)methyl]-6-hydroxy-1,3-benzothiazol-2(3H)-one
  参考文献：
  名称：

  [EN] SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
  [FR] 1,3-BENZOTHIAZOL-2(3H)-ONES ET [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES SUBSTITUÉES FORMANT DES EFFECTEURS ALLOSTÉRIQUES POSITIFS DE MGLUR2

  摘要：

  本发明涉及苯并噻唑酮和噻唑吡啶酮衍生物，它们是代谢型谷氨酸受体的增效剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及代谢型谷氨酸受体参与的疾病方面具有用处。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病方面的用途。

  公开号：

  WO2011137046A1
• 作为产物：
  描述：

  6-溴-2-苯并噻唑啉酮 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride potassium acetate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 为溶剂， 反应 36.0h， 生成 3-[(2,2-difluorocyclopropyl)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2(3H)-one
  参考文献：
  名称：

  [EN] SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
  [FR] 1,3-BENZOTHIAZOL-2(3H)-ONES ET [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES SUBSTITUÉES FORMANT DES EFFECTEURS ALLOSTÉRIQUES POSITIFS DE MGLUR2

  摘要：

  本发明涉及苯并噻唑酮和噻唑吡啶酮衍生物，它们是代谢型谷氨酸受体的增效剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及代谢型谷氨酸受体参与的疾病方面具有用处。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病方面的用途。

  公开号：

  WO2011137046A1

文献信息

• Substituted 1,3-Benzothiazol-2(3H)-Ones and [1,3]Thiazolo[5,4-B]Pyridin-2(IH)-Ones as Positive Allosteric Modulators of MGLUR2
  申请人：Layton Mark E.

  公开号：US20130035332A1

  公开（公告）日：2013-02-07

  The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及苯并噻唑-1和噻唑吡啶-1衍生物，它们是代谢型谷氨酸受体增强剂，特别是mGluR2受体的增强剂，并且在治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病方面具有用途。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病方面的用途。
• SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
  申请人：LAYTON MARK E.

  公开号：US20140045829A1

  公开（公告）日：2014-02-13

  The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及苯并噻唑酮和噻唑吡啶酮衍生物，它们是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，并且它们在治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病中非常有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗代谢型谷氨酸受体参与的这些疾病中使用这些化合物和组合物。
• Substituted 1,3-benzothiazol-2(3H)-ones and [1,3]thiazolo[5,4-B]pyridin-2(1H)-ones as positive allosteric modulators of mGluR2
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08952005B2

  公开（公告）日：2015-02-10

  The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及苯并噻唑-1和噻唑吡啶-1衍生物，它们是代谢性谷氨酸受体的增强剂，特别是mGluR2受体，并且它们在治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及与代谢性谷氨酸受体有关的疾病方面非常有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及代谢性谷氨酸受体的疾病方面使用这些化合物和组合物。
• [EN] SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2<br/>[FR] 1,3-BENZOTHIAZOL-2(3H)-ONES ET [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES SUBSTITUÉES FORMANT DES EFFECTEURS ALLOSTÉRIQUES POSITIFS DE MGLUR2
  申请人：MERCK SHARP & DOHME

  公开号：WO2011137046A1

  公开（公告）日：2011-11-03

  The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及苯并噻唑酮和噻唑吡啶酮衍生物，它们是代谢型谷氨酸受体的增效剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及代谢型谷氨酸受体参与的疾病方面具有用处。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病方面的用途。